SAN DIEGO, Feb. 8 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, today announced that John P. Longenecker, Ph.D., President and Chief Executive Officer, will participate in a focus session entitled “Cancer Immunotherapies Coming of Age” at the Biotechnology Industry Organization’s 8th Annual BIO CEO & Investor Conference at 9:00 a.m. EST on Tuesday, February 14, 2006. The conference will be held at The Waldorf=Astoria in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO)
Dr. Longenecker will be joined on the panel by Alex McPherson, M.D., Ph.D., President and Chief Executive Officer, Biomira Inc., Peter Working, Ph.D., Senior Vice President, Research and Development, Cell Genesys, Inc., Mitchell Gold, M.D., President and Chief Executive Officer, Dendreon Corporation, and Hyam Levitsky, M.D., Professor of Oncology, Johns Hopkins University School of Medicine. Mark Monane, M.D., Managing Director of Equity Research, Biotechnology and Life Sciences, Needham and Company, LLC, will serve as the panel’s moderator.
A webcast recording of the focus session can be accessed at www.favrille.com or http://ceo.bio.org/opencms/ceo/2006/index.jsp. The webcast recording will be available approximately 12 hours after the presentation and will be archived until March 14, 2006.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of T-cell lymphoma.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.
CONTACT: Pete De Spain Associate Director, Investor Relations & CorporateCommunications of Favrille, Inc., +1-858-526-2426, pdespain@favrille.com
Web site: http://www.favrille.com//
